amlodipine nicotinate

05/01/2008 - "The aim of this study was to compare the efficacy and safety profiles of S(-)-amlodipine nicotinate with those of amlodipine besylate in adult Korean patients with mild to moderate hypertension (diastolic blood pressure [DBP] >or=90 mm Hg and <or=109 mm Hg). "
09/01/2012 - "Female patients with mild to moderate hypertension were randomly assigned to receive either S(-)-amlodipine nicotinate 2.5 to 5 mg once daily or amlodipine besylate 5 to 10 mg once daily for 12 weeks. "
05/01/2008 - "The reduction of SiDBP after 8 weeks of treatment with S(-)-amlodipine nicotinate was noninferior compared with that of racemic amlodipine besylate in these adult Korean patients with mild to moderate hypertension. "
05/01/2008 - "Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial."
09/01/2012 - "This exploratory study compared the amount of pedal edema experienced by female Korean patients with mild to moderate hypertension when receiving S(-)-amlodipine nicotinate compared with amlodipine besylate. "

09/01/2012 - "This exploratory study compared the amount of pedal edema experienced by female Korean patients with mild to moderate hypertension when receiving S(-)-amlodipine nicotinate compared with amlodipine besylate. "
09/01/2012 - "These female Korean patients with hypertension taking S(-)-amlodipine nicotinate had less ankle edema, with no significant difference in BP-lowering efficacy, compared with those taking amlodipine besylate. "
09/01/2012 - "Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical trial."

05/01/2008 - "The most common ADRs were liver enzyme elevation (3/63 [4.8%]) in the S(-)-amlodipine nicotinate group and facial flushing (3/61 [4.9%]) in the amlodipine besylate group. "

01/01/2014 - "It is established that S-amlodipine nicotinate produces a somewhat more pronounced enhancement of cerebral blood flow in rats with ischemic and hemorrhagic brain injury than in intact animals. "
01/01/2014 - "[Effect of S-amlodipine nicotinate on the cerebral circulation in rats under conditions of ischemic and hemorrhagic brain injury]."
01/01/2014 - "We have performed a comparative study of the effects of S-amlodipine nicotinate and nimodipine on the local cerebral blood flow were studied in intact rats and those with model ischemic and hemorrhagic brain injury. "